1 / 39

Managing Acute Heart Failure: Challenges and Strategies for Better Outcomes

Explore the vulnerable phase post-acute heart failure and the impact of early mortality. Discover treatment goals and prognostic criteria as per ESC guidelines, focusing on biomarkers, GDMT, and Sacubitril/Valsartan benefits. Delve into study designs and populations to enhance future management approaches.

toone
Download Presentation

Managing Acute Heart Failure: Challenges and Strategies for Better Outcomes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What Comes Next After Stabilized Acute Heart Failure?

  2. Introduction

  3. Program Overview

  4. Vulnerable Phase After HHF

  5. Mortality Is High in the Early Phase After HHF

  6. Vulnerable Phase After HHF: Challenges

  7. Acute HF: Goals of Treatment

  8. Contribution of Acute Events to the Progression of HF

  9. Hospitalization for Acute HF

  10. Prognostic Criteria for Poor Outcomes in Patients With ADHF

  11. Potential Uses of Biomarkers in Patients With Acute HF

  12. In-Hospital Mortality in Patients With HF

  13. Clinical Characteristics of Patients With HF: Europe and United States

  14. GDMT for HF: The Evidence Exists But Utilization Is Low

  15. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic HF

  16. Predischarge Initiation of Carvedilol in Patients Hospitalized for ADHF: IMPACT-HF

  17. Carvedilol Use At Discharge in Patients With ADHF Is Associated With Improved Survival: OPTIMIZE-HF

  18. Sacubitril/Valsartan Mechanism of Action

  19. Benefit of ARNI in HFrEF: Results of the PARADIGM-HF Trial

  20. Benefit of ARNI in HFrEF: Results of the PARADIGM-HF Trial (cont)

  21. PARADIGM-HF Study Design

  22. Challenges to Incorporating Sacubitril/Valsartan Into Clinical Practice

  23. Trials With Sacubitril/Valsartan in Patients With HFrEF

  24. PIONEER-HF: Study Design

  25. PIONEER-HF: Study Endpoints

  26. PIONEER-HF: Change in NT-proBNP Concentration Over Time (Primary Endpoint)

  27. PIONEER-HF: Additional Outcomes

  28. PIONEER-HF: Conclusions

  29. TRANSITION: Study Design

  30. TRANSITION: Study Endpoints

  31. TRANSITION: Important Observations

  32. TRANSITION: Conclusions

  33. Unique Populations of Patients With Acute HF

  34. Future Management of Patients With Acute HF

  35. Evidence-Based Guidelines: Use of Sacubitril/Valsartan

  36. Program Summary

  37. Abbreviations

  38. Abbreviations (cont)

  39. Abbreviations (cont)

More Related